(c) REGULATIONS.—The Secretary of Health and 
Human Services, acting through the Commissioner of 
Food and Drugs, shall promulgate regulations to carry out 
subparagraph (B) of section 303(g)(1) of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 333(g)(1)), as 
added by subsection (a). Such regulations shall include 
provisions setting forth— 
(1) a reasonable amount of time a manufac-
turer has to update any direct-to-consumer adver-
tising of a drug in accordance with such subpara-
graph (B) after a change to the wholesale acquisi-
tion cost of the drug; and 
(2) the specific manner in which the wholesale 
acquisition cost of a drug is required to be conspicu-
ously disclosed in such direct-to-consumer advertise-
ments in order to communicate such single price 
metric to the public, which shall include visual and 
audio (as applicable) components of the advertise-
ment, and which may include a brief qualitative ex-
planation of reduced cost availability for certain con-
sumers, such as through insurance cost-sharing ar-
rangements or patient assistance programs. 
VerDate Sep 11 2014 
23:39 Aug 09, 2018
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6576.IH
H6576
pamtmann on DSKBFK8HB2PROD with BILLS
SEC. 4. DRUG MANUFACTURER DUTY TO DISCLOSE DRUG 
PRICES TO PRACTITIONERS. 
(a) DUTY TO DISCLOSE.—Whenever a drug manu-
facturer, including any representative of the manufac-
turer, communicates with a health care practitioner about 
a drug manufactured by the drug manufacturer, including 
through promotional, educational, or marketing commu-
nications, meetings or paid events, and the provision of 
goods, gifts, and samples, the drug manufacturer shall dis-
close to the practitioner the wholesale acquisition cost (as 
defined in section 1847A(c)(6)(B) of the Social Security 
Act (42 U.S.C. 1395w–3a(c)(6)(B))) for a 30-day supply 
of the drug, which may include a brief qualitative expla-
nation of reduced cost availability for certain consumers 
that is consistent with the regulations described in section 
3(c)(2). 
(b) ENFORCEMENT BY FEDERAL TRADE COMMIS-
SION.— 
(1) UNFAIR
OR
DECEPTIVE
ACTS
OR
PRAC-
TICES.—A violation of subsection (a) by a person 
with respect to whom the Commission is empowered 
under section 5(a)(2) of the Federal Trade Commis-
sion Act (15 U.S.C. 45(a)(2)) shall be treated as a 
violation of a rule defining an unfair or deceptive act 
or practice prescribed under section 18(a)(1)(B) of 
VerDate Sep 11 2014 
23:39 Aug 09, 2018
Jkt 079200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6576.IH
H6576
pamtmann on DSKBFK8HB2PROD with BILLS
the Federal Trade Commission Act (15 U.S.C. 
57a(a)(1)(B)). 
(2) POWERS
OF
FEDERAL
TRADE
COMMIS-
SION.— 
(A) IN
GENERAL.—The Federal Trade 
Commission shall enforce this section in the 
same manner, by the same means, and with the 
same jurisdiction, powers, and duties as though 
all applicable terms and provisions of the Fed-
eral Trade Commission Act (15 U.S.C. 41 et 
seq.) were incorporated into and made a part of 
this Act. 
(B) PRIVILEGES
AND
IMMUNITIES.—Any 
person who violates this section shall be subject 
to the penalties and entitled to the privileges 
and immunities provided in the Federal Trade 
Commission Act (15 U.S.C. 41 et seq.). 
(c) RULEMAKING.—The Federal Trade Commission 
shall promulgate in accordance with section 553 of title 
5, United States Code, such rules as may be necessary 
to carry out this section. 
(d) SAVINGS PROVISION.—Nothing in this section 
shall be construed to limit, impair, or supersede the oper-
VerDate Sep 11 2014 
23:39 Aug 09, 2018
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6576.IH
H6576
pamtmann on DSKBFK8HB2PROD with BILLS
ation of the Federal Trade Commission Act or any other 
provision of Federal law. 
Æ 
VerDate Sep 11 2014 
23:39 Aug 09, 2018
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6301
E:\BILLS\H6576.IH
H6576
pamtmann on DSKBFK8HB2PROD with BILLS